T-686, a novel inhibitor of plasminogen activator inhibitor-1, inhibits thrombosis without impairment of hemostasis in rats

European Journal of Pharmacology

Volumn 330, Issue 2-3, 1997, Pages 151-156

  Ohtani, Akio ^a   Murakami, Jun ^a   Hirano Wakimoto, Ayako ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Fibrinolysis; Hemostasis; PAI 1 (plasminogen activator inhibitor 1); Rat; Thrombus

Indexed keywords

3 BENZYLIDENE 4 (3,4,5 TRIMETHOXYBENZYLIDENE)SUCCINIMIDE; ANTICOAGULANT AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; TICLOPIDINE; UNCLASSIFIED DRUG; WARFARIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING TIME; BLOOD CLOTTING TIME; CONTROLLED STUDY; HEMOSTASIS; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; THROMBOCYTE AGGREGATION; THROMBOSIS;

ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; ARTERIOVENOUS SHUNT, SURGICAL; BENZYLIDENE COMPOUNDS; BLEEDING TIME; FIBRINOLYTIC AGENTS; HEMOSTASIS; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RABBITS; RATS; RATS, WISTAR; SERINE PROTEINASE INHIBITORS; SUCCINIMIDES; THROMBOPHLEBITIS; TICLOPIDINE; WARFARIN;

EID: 0030796987     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)00174-X     Document Type: Article

References (26)

1. Abrahamsson T., Nerme V., Stromqvist M., Akerblom B., Legnehed A., Pettersson K., Westin Eriksson A. Anti-thrombotic effect of a PAI-1 inhibitor in rats given endotoxin. Thromb. Haemost. 75:1996;118-126.
2. Avellone G., DiGarbo V., Cordova R., Panno A.V., Raneli G., DeSimone R., Bompiani G.D. Fibrinolytic effect of gemfibrozil versus placebo administration in response to venous occlusion. Fibrinolysis. 7:1993;416-421.
3. Biemond B.J., Levi M., Coronel R., Janse M.J., Ten Cate J.W., Pannekoek H. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody. Circulation. 1:1995;1175-1181.
4. Born G.V.R. Aggregation of blood platelet by adenosine diphosphate and its reversal. Nature. 194:1962;927-929.
5. Brown S.L., Sobel B.E., Fujii S. Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. Circulation. 92:1995;767-772.
6. Carmeliet P., Stassen J.M., Schoonjans L., Ream B., Van den Oord J.J., De Mol M., Mulligan R.C., Collen D. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis and thrombolysis J. Clin. Invest. 92:1993;2756-2760.
7. Chmielewska J., Ranby M., Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb. Res. 31:1983;427-436.
8. Fay W.P., Shapiro A.D., Shih J.L., Schleef R.R., Ginsburg D. Complete deficiency of plasminogen activator inhibitor type-1 due to a frame-shift mutation. New Engl. J. Med. 327:1992;1729-1733.
9. Freiman, D.G., 1982. The structure of thrombi. In: Colman, R.W., Marder, V.J., Salzman, E.W. (Eds.), Hemostasis and Thrombosis, Basic Principles and Clinical Practice. J.B. Lippincatt, Co., Philadelphia - Toronto, p. 767.
10. Fujii S., Sawa H., Sobel B.E. Inhibition of endothelial cell expression of plasminogen activator inhibitor type-1 by gemfibrozil. Thromb. Haemost. 70:1993;642-647.
11. Juhan-Vague I., Valadier J., Alessi M.C., Aillaud M.F., Ansaldi J., Philip-Joet C., Holvoet J., Serradimigni A., Collen D. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent venous thrombosis. Thromb. Haemost. 57:1987;67-72.
12. Krishnamurti C., Barr C.F., Hassett M.A., Young G.D., Alving B.M. Plasminogen activator inhibitor; a regulator of ancord-induced fibrin deposition in rabbits. Blood. 69:1987;798-803.
13. Levi M., Biemond B.J., Van Zonnenveld A.J., Ten Cate J.W., Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation. 85:1992;305-312.
14. Nilsson I.M., Ljungner H., Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br. J. Med. 290:1985;1453-1456.
15. Odawara A., Katoh M., Karasawa T., Tamura K., Sasaki Y. Inhibitory effect of clentiazem (TA-3090) on platelet aggregation - alone and in combination with aspirin or ticlopidine. Thromb. Res. 75:1994;109-119.
16. Ohtani A., Murakami J. A novel inhibitor of plasminogen activator inhibitor-1 production, T-686: direct effects on the fibrinolytic system. Fibrinolysis Proteolysis. 11:1997;45-50.
17. Ohtani A., Takagi T., Hirano A., Murakami J., Sasaki Y. Inhibitory effect of a new butadiene derivative on the production of plasminogen activator inhibitor-1 in cultured bovine endothelial cells. J. Biochem. 120:1996;1203-1208.
18. Padro T., Quax P.H.A., Van den Hoogen C.M., Roholl P., Verheijen J.H., Emeis J.J. Tissue-type plasminogen activator and its inhibitor in rat aorta; effect of endotoxin. Arterioscler. Thromb. 14:1994;1459-1465.
19. Reilly C.F., Fujita T., Mayer E.F., Siegfried M.E. Both circulating and clot-bound plasminogen activator inhibitor-1 inhibit endogenous fibrinolysis in the rat. Arterioscler. Thromb. 11:1991;1276-1286.
20. Reyers I., Mussoni L., Donati M.B., De Gaetano G. Failure of aspirin at different doses to modified experimental thrombosis in rats. Thromb. Res. 18:1980;669-674.
21. Schneider J., Loskutoff D.J. Plasminogen activator inhibitors. Trends Cardiovasc. Med. 1:1991;99-102.
22. Umetsu T., Sanai K. Effect of 1-methyl-2-mercapto-5-(3-pyridyl)-imidazole (KC-6141), an anti aggregating compound, on experimental thrombosis in rats. Thromb. Haemost. 39:1978;74-83.
23. Vinogradsky B., Bell S.P., Woodcock-Mitchell J., Ohtani A., Fujii S. A new butadiene derivative, T-686, inhibits plasminogen activator inhibitor type-1 production in vitro by cultured human vascular endothelial cells and development of atherosclerotic lesions in vivo in rabbits. Thromb. Res. 85:1997;305-314.
24. Vogel G.M.T., Meuleman D.G., Bourgondien F.G.M., Hobbelen P.M.J. Comparison of two experimental thrombosis models in rats. Effects of four glycosaminoglycans. Thromb. Res. 54:1989;399-410.
25. Wieczorek I., Ludlam C.A., Fox K.A.A. Tissue-type plasminogen activator and plasminogen activator inhibitor activities as predictors of adverse events in unstable angina. Am. J. Cardiol. 74:1994;424-429.
26. Wiman B., Ljungberg S., Chmielewska J., Urden G., Blomback M., Johnsson H. The role of fibrinolytic system in deep vein thrombosis. J. Lab. Clin. Med. 105:1985;265-270.